Amicus Therapeutics (NASDAQ:FOLD) Insider Ellen Rosenberg Sells 36,000 Shares

Amicus Therapeutics, Inc. (NASDAQ:FOLD) insider Ellen Rosenberg sold 36,000 shares of the company’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $10.00, for a total transaction of $360,000.00. Following the completion of the transaction, the insider directly owned 507,710 shares in the company, valued at $5,077,100. The trade was a 6.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Ellen Rosenberg also recently made the following trade(s):

• On Wednesday, November 26th, Ellen Rosenberg sold 23,621 shares of Amicus Therapeutics stock. The shares were sold at an average price of $10.00, for a total transaction of $236,210.00.

Amicus Therapeutics Trading Up 1.5%

Shares of Amicus Therapeutics stock traded up $0.15 on Wednesday, reaching $10.02. The company had a trading volume of 3,136,374 shares, compared to its average volume of 4,236,660. The firm’s 50 day moving average price is $8.73 and its two-hundred day moving average price is $7.34. The company has a debt-to-equity ratio of 1.92, a quick ratio of 2.29 and a current ratio of 3.21. Amicus Therapeutics, Inc. has a 52-week low of $5.51 and a 52-week high of $10.57. The firm has a market cap of $3.09 billion, a PE ratio of -83.49 and a beta of 0.66.

Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.05. The firm had revenue of $169.06 million during the quarter, compared to the consensus estimate of $165.24 million. Amicus Therapeutics had a negative net margin of 6.67% and a negative return on equity of 5.07%. The firm’s revenue for the quarter was up 19.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.10 EPS. Amicus Therapeutics has set its FY 2025 guidance at EPS. Sell-side analysts predict that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Amicus Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Osaic Holdings Inc. increased its stake in Amicus Therapeutics by 450.1% in the second quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 3,358 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Amicus Therapeutics by 472.6% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 3,677 shares in the last quarter. Strs Ohio acquired a new position in shares of Amicus Therapeutics in the 1st quarter valued at $30,000. ANTIPODES PARTNERS Ltd purchased a new position in shares of Amicus Therapeutics in the 3rd quarter valued at $31,000. Finally, Versant Capital Management Inc raised its stake in Amicus Therapeutics by 499.1% during the 3rd quarter. Versant Capital Management Inc now owns 5,266 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 4,387 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. lifted their price objective on Amicus Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Needham & Company LLC raised Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research report on Thursday, September 18th. Wall Street Zen upgraded shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Zacks Research raised shares of Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. Finally, The Goldman Sachs Group lifted their price objective on shares of Amicus Therapeutics from $9.00 to $11.00 and gave the company a “neutral” rating in a report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Amicus Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $16.57.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.